Italian pharmaceutical company DuLac Farmaceutici is accelerating its expansion into the U.S. market, announcing that its products are now available through OneLavi.com as the company prepares to participate in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, scheduled for September 14-17 in Palm Beach Gardens, Florida. These two developments represent significant steps in DuLac's strategy to broaden its U.S. footprint, following established consumer demand on Amazon.
DuLac views the United States as a key long-term growth market and is approaching its expansion with a multi-channel strategy. Rather than relying solely on e-commerce, the company is combining its Amazon presence, the new OneLavi channel, and direct engagement with retailers and distribution partners through ECRM. This approach aims to build a diversified national presence across various distribution channels.
Gabriele Bollani, Founder and CEO of DuLac Farmaceutici, emphasized the importance of this phase: "ECRM comes at an important time for DuLac because we are making a major commitment to the U.S. market. Amazon has demonstrated that American consumers are responding to our products, OneLavi gives us another important U.S. channel, and now we are ready to introduce DuLac to major retailers and build the partnerships that can take our expansion to the next level."
The company's entry into the U.S. market has been bolstered by strong consumer response on Amazon. Notably, its Arnica Gel 98% has garnered over 13,000 customer reviews with an average 4.5-star rating, while the Dinaven line has received more than 4,000 reviews and maintains a 4.6-star average. This existing demand provides a solid foundation as DuLac introduces its products to a wider audience through OneLavi and potential retail partners.
Participation in the ECRM session will allow DuLac to engage in scheduled meetings with buyers from major health, specialty, food, drug, and mass retail channels. The company plans to showcase its Italian-developed portfolio, including its high-concentration Arnica Gel 98% range and the Dinaven and Diosmin lines, along with its pharmaceutical heritage and advanced manufacturing capabilities. The goal is to establish relationships that can support a much larger and more diversified U.S. retail presence.
DuLac brings over 30 years of pharmaceutical industry expertise and pharmacy-channel experience in Italy to its U.S. expansion. The company's product development and manufacturing capabilities include its proprietary Arnica Montana Arricchita™ project, indoor vertical farming, micronized Diosmin MPFF technology, solvent-free Supercritical CO₂ Extraction, and manufacturing under internationally recognized GMP and ISO quality frameworks. This combination of Italian pharmaceutical innovation, advanced production technologies, and established U.S. consumer demand positions DuLac for its next stage of growth.
With Amazon already established, OneLavi now live, and scheduled meetings with major retail buyers planned through ECRM, DuLac is moving from initial market development toward a broader national expansion strategy. The company aims to build a diversified U.S. presence across e-commerce, retail, wholesale, and other channels, introducing more American consumers to the DuLac brand and its Italian-developed product portfolio.
